ClinicalTrials.gg
RecruitingNCT06905587EMBRAINUpdated Nov 3, 2026

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

A Phase 3 interventional study of Methylphenidate (MPH) and Placebo in Brain Tumor, Pediatric, Cancer-related Fatigue and Methylphenidate, sponsored by Odense University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 6 Years to 27 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Odense University Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 3, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
6 Years to 27 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies in Brain Neoplasms with a site in Denmark — 10 open to participants now, 14 under way, 3 of them phase 3. Brain Neoplasms · Denmark.

Planned enrollment
18th of 27
50 · median 80
Started
2025
with 1 other
Phase 3
6 of 38
1 open now
Primary completion
2029-12
later than 10 of 13 live
Registered
34th of 38
by date
Lead sponsor
2 of 38
Odense University Hospital

Among the 38 studies in Brain Neoplasms with a site in Denmark, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 10 of the 13 other live ones, and was the 34th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

10 of the 38 studies in Brain Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 27 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Brain Neoplasms with a site in Denmark, or all of them as a file.
02

Study summary

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

03

Conditions studied

  • Brain Tumor, Pediatric
  • Cancer-related Fatigue
  • Methylphenidate

Keywords

  • methylphenidate
  • cancer-related fatigue
  • brain tumor
  • childhood cancer
  • pediatric cancer
  • childhood cancer survivor
  • late effect
  • long-term effects secondary to cancer therapy in children
  • long-term effects of cancer-treatment
  • pediatric brain tumor
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
6 Years to 27 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  2. Treated for a brain tumor during the previous 10 years.
  3. Age ≥6 years and \<28 years at the start of the trial.
  4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
  5. No known signs of clinical or radiological tumor progression at last follow-up.
  6. Danish is the sole or primary language (enabling provision of validated assessment tools).
  7. Patient and family have provided consent for inclusion in the trial.
  8. fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
  9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion criteria

Exclusion Criteria:

  1. Any known to methylphenidate as outlined below:

    A) to the active substance or any listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

  2. History of recent poorly controlled seizures.
  3. Complex tics or Tourette syndrome (including family history of tic disorder).
  4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.
  5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of \<50.
  6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.
  7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.
  8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).
  9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Methylphenidate, Then Placebo

    Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

    Drug: Methylphenidate (MPH) · Drug: Placebo

  • Experimental
    Placebo, Then Methylphenidate

    Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

    Drug: Methylphenidate (MPH) · Drug: Placebo

Interventions

  • DrugMethylphenidateStudies of MethylphenidateMethylphenidate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally. For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

  • DrugPlacebo

    10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally. Dosage will follow the exact same principles as for the study drug (methylphenidate).

06

What researchers measure

Primary outcomes

  1. PedsQL Multidimensional Fatigue Scale (MFS)

    Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).

    Time frame: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Secondary outcomes

  1. PedsQL Multidimensional Fatigue Scale (MFS)

    Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.

    Time frame: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

  2. Behaviour Rating Inventory of Executive Function (BRIEF)

    Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.

    Time frame: At baseline, at Week 6, and Week 16.

  3. Connor's Continuous Performance Test (CPT) Online Suite

    Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.

    Time frame: At baseline, at Week 6, and Week 16.

  4. Wechsler Coding

    Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.

    Time frame: At baseline, at Week 6, and Week 16.

  5. Wechsler Digit Span

    Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.

    Time frame: At baseline, at Week 6, and Week 16.

  6. PedsQL Generic Core Scales

    Changes from baseline in self and parent-reported measures of Health Related Quality of Life.

    Time frame: At baseline, at Week 6, and Week 16.

  7. Accelerometry (Axivity AX3)

    Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.

    Time frame: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.

  8. Barkley's Stimulant Side Effect Rating Scale (SSERS)

    Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.

    Time frame: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2029, 51 months after the start.

Of 56 phase 3 interventional studies under Brain Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 269. This study's planned 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Apr 1, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Aalborg University Hospital is now Recruiting
Nov 3, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedTreated for a PBTbrain tumor during the previous 10 years, starting from date of diagnosis.
  • EditedAgedAge ≥6 years 0 monthsand <28 years at the start of the trial.
Exclusion criteria
  • EditedMotorComplex tics or Tourette syndrome (including family history of tic disorder).
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Aalborg University Hospital · Aalborg, DenmarkContact e•••@rn.dk · •••4983→c•••@rn.dk · •••3368Contact person changed (no phone or email listed)
Nov 3, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Aalborg University Hospital is now Recruiting
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedTreated for a PBTbrain tumor during the previous 10 years, starting from date of diagnosis.
    • EditedAgedAge ≥6 years 0 monthsand <28 years at the start of the trial.
    Exclusion criteria
    • EditedMotorComplex tics or Tourette syndrome (including family history of tic disorder).
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Aalborg University Hospital · Aalborg, DenmarkContact e•••@rn.dk · •••4983→c•••@rn.dk · •••3368Contact person changed (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06905587
Collaborators
Aarhus University Hospital Skejby, Aalborg University Hospital, Copenhagen University Hospital, Rigshospitalet, University of Southern Denmark
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Sep 2, 2025
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Sebastian W Most-Mottelson, MD, PhD Student
Contact
sebastian.wenzel.most-mottelson@rsyd.dk
+45 21567257
Mathias Rathe, Consultant, MD, PhD
Contact
mathias.rathe@rsyd.dk
+45 20469682
Mathias Rathe, Consultant, MD, PhD
study director · Odense University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylphenidate

Start the discussion